sulfadoxine-pyrimethamine

In this issue of the journal, Maiga et al report on a randomized clinical trial performed in Mali, which shows the superiority of 3 over 2 doses of IPTp SP for the prevention of placenta malaria and associated low birth weight infants.

This study evaluates the effectiveness of IPTp-SP among pregnant women attending the antenatal clinic at Korle-Bu Teaching Hospital in Accra, Ghana.

We enrolled 1,320 pregnant women into a randomized, controlled trial in Malawi to study whether preterm delivery and low birth weight (LBW) incidence can be reduced by intermittent preventive treatment of maternal malaria and reproductive tract infections.

The high "quintuple" mutation prevalence suggests a limited useful therapeutic lifespan of AS-SP for treating uncomplicated malaria, and may curb efficacy of SP-monotherapy for intermittent preventive treatment in Mozambique.

We discuss IPT with SP in light of several concerns and highlight recent findings from a pharmacokinetic study of SP in this population.

The evolution of resistance in Plasmodium falciparum against safe and affordable drugs such as chloroquine (CQ) and sulfadoxine-pyrimethamine (SP) is a major global health threat.

Intermittent preventive treatment (IPT) is a promising strategy for previous termmalarianext term control in infants. We undertook a pooled analysis of the safety and efficacy of IPT in infants (IPTi) with sulfadoxine-pyrimethamine in Africa.